The expression of P16, P53, and PTEN in polyps (including those undergoing endocrine therapy in premenopausal and postmenopausal women), sporadic polyps, and endometrial carcinoma.

Postmenopausal polyps; 7. Premenopausal endometrial cancer; 8. Postmenopausal endometrial cancer), age (unit: years), whether menopause (1: yes, 2: no), BMI: keep 2 decimal places (unit: Kg/m2), number of deliveries, hypertension (1: yes, 2: no), diabetes (1: yes, 2: no), abnormal uterine bleeding (1: yes, 2: no), type of medication (1, TAM; 2, TOR), time of medication (unit: month), endometrial thickness (unit: mm), maximum diameter of uterine space occupation (unit: mm), pathological results, The percentage of positive cells for P16, P53, PTEN glands (≤ 10% is 1 point, 10%~50% is 2 points, 50%~75% is 3 points,>75% is 4 points), staining intensity ("-" is 0 points, "+" is 1 point, "++" is 2 points, "+++" is 3 points), staining score (percentage of positive cells

• staining intensity), staining grade (0-3 points are negative, 3-6 points are+, 6-8 points are++, 8-12 points are++++, negative is 0 points, "+" is 1 point, "++" is 2 points, "+++" is 3 points), partial endometrial cancer, sporadic The lack of medication types and duration for endometrial polyps is in accordance with the experimental design and should not be treated.